This article refers to:
In the review “RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases”, published in the April 2009 issue of Expert Opinion on Biological Therapy (Expert Opin. Biol. Ther. (2009) 9(4):465-79), it has brought to our attention that the following acknowledgement should have been included:
“Amgen Hellas supported the inclusion of colour figures in this manuscript.”
Informa Healthcare and the authors of this article would like to apologise for the original omission.